The diagnosis and management of gastrointestinal cancers has dramatically changed in the past several years. By incorporating biotechnology, bioinformatics, molecular biomarker analyses, pharmocogenomic data, in the setting of prospective clinical trials, we may better identify patients who will benefit from chemotherapy, avoid toxicities from treatment, and develop a predictive therapeutic strategy unique to a patient’s disease. Enrollment of patients with cancers of the colon, rectum, anus, stomach, esophagus, GI stromal tumors, hepatocellular carcinoma, pancreas, gall-bladder, and cholangiocarcinoma into our clinical trials is a priority.
Education & Training
BS - Biology/Chemistry/Math, University of Arizona - 1983
MS - Microbiology/Immunology, University of Arizona - 2001
MD - University of Arizona - 2001
Resident - Scripps-Green Hospital, La Jolla, CA - 2001-2004
Fellowship - Hematology-Oncology, Scripps Clinic, La Jolla, CA - 2004-2007